Technical Analysis for CLYYF - Celyad Oncology Sa
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | N/A |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Hot IPO Pullback | Bullish Swing Setup | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -27.70% | |
| Narrow Range Bar | Range Contraction | -27.70% | |
| New 52 Week Low | Weakness | -27.70% | |
| Gapped Down | Weakness | -27.70% | |
| Narrow Range Bar | Range Contraction | -46.73% |
Get a Trading Assistant
Celyad Oncology Sa Description
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Classification
Sector: Healthcare
Industry: Biotechnology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.7377 |
| 52 Week Low | 0.393 |
| Average Volume | 224 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0000 |
| 20-Day Moving Average | 0.0000 |
| 10-Day Moving Average | 0.0000 |
| Average True Range | 0.0000 |
| RSI (14) | 0.00 |
| ADX | 0.0 |
| +DI | 0.0000 |
| -DI | 0.0000 |
| Chandelier Exit (Long, 3 ATRs) | N/A |
| Chandelier Exit (Short, 3 ATRs) | N/A |
| Upper Bollinger Bands | 0.0000 |
| Lower Bollinger Band | 0.0000 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0000 |
| MACD Line | 0.0000 |
| MACD Signal Line | 0.0000 |
| MACD Histogram | 0.0 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.3930 | ||||
| Resistance 3 (R3) | 0.3930 | 0.3930 | 0.3930 | ||
| Resistance 2 (R2) | 0.3930 | 0.3930 | 0.3930 | 0.3930 | |
| Resistance 1 (R1) | 0.3930 | 0.3930 | 0.3930 | 0.3930 | 0.3930 |
| Pivot Point | 0.3930 | 0.3930 | 0.3930 | 0.3930 | 0.3930 |
| Support 1 (S1) | 0.3930 | 0.3930 | 0.3930 | 0.3930 | 0.3930 |
| Support 2 (S2) | 0.3930 | 0.3930 | 0.3930 | 0.3930 | |
| Support 3 (S3) | 0.3930 | 0.3930 | 0.3930 | ||
| Support 4 (S4) | 0.3930 |
